Analysis of changes in the levels of soluble molecules CD50, CD54 and CD95 in the blood serum of patients with uterine fibroids depending on the characteristics of the disease (pilot study)

Background. Currently, the search for circulating immunological and inflammatory markers that play a significant role in the pathogenesis of uterine fibroids (UF) is relevant.

Aim. Changes in the serum levels of soluble molecules CD50 (sCD50), CD54 (sCD54) and CD95 (sCD95) in patients with UF depending on the characteristics of the disease.

Materials and methods. The study involved 78 patients with UF aged 31–59 years and 45 clinically healthy women of comparable age. The patients were divided into the following groups depending on the localization of the myomatous node: interstitial-subserous localization (n = 17), subserous localization (n = 16), submucosal localization (n = 15), interstitial-submucosal localization (n = 15), interstitial localization (n = 15). In 34.6 % patients, the number of myoma nodes was 4–6, in 46.2 % women there were 2–3 nodes, in 19.2 % – 1 node.

Determination of the serum concentration of sCD50, sCD54 and sCD95 molecules was performed using a two-site enzyme immunoassay and expressed in conventional units (U / ml).

Results. The average serum concentration of sCD95, sCD54 and sCD50 in all patients with UF was significantly higher than in the control group (p <0.05). The maximum level of the tested molecules was found in UF patients with submucosal localization and the presence of one myomatous node.

Conclusions. The detected increase in sCD50, sCD54 and sCD95 levels in UF patients indicates the participation of these proteins in the immunopathogenesis of this pathology. The imbalance in studied proteins levels is most pronounced in submucosal localization of fibroids, which may indicate an unfavorable course of the disease and serve as an additional criterion for selecting patients in the preoperative period.

1. Mathew R.P., Francis S., Jayaram V., Anvarsadath S. Uterine leiomyomas revisited with review of literature. Abdom Radiol (NY) 2021;46(10):4908–26. DOI: 10.1007/s00261-021-03126-4

2. Dvorská D., Škovierová H., Braný D. et al. Liquid biopsy as a tool for differentiation of leiomyomas and sarcomas of corpus uteri. Int J Mol Sci 2019;20(15):3825. DOI: 10.3390/ijms20153825

3. AlAshqar A., Reschke L., Kirschen G.W., Borahay M.A. Role of inflammation in benign gynecologic disorders: from pathogenesis to novel therapies. Biol Reprod 2021;105(1):7–31. DOI: https://doi.org/10.1093/biolre/ioab054

4. Sahar T., Nigam A., Anjum S. et al. Interactome analysis of the differentially expressed proteins in uterine leiomyoma. Anticancer Agents Med Chem 2019;19(10):1293–312. DOI: 10.2174/1871520619666190206143523

5. Governini L., Marrocco C., Semplici B. et al. Extracellular matrix remodeling and inflammatory pathway in human endometrium: insights from uterine leiomyomas. Fertil Steril 2021; 116 (5): 1404–14. DOI: 10.1016/j.fertnstert.2021.06.023

6. Protic O., Toti P., Islam M.S. et al. Possible involvement of inflammatory/reparative processes in the development of uterine fibroids. Cell Tissue Res 2016;364(2):415–27. DOI: 10.1007/s00441-015-2324-3

7. Zannotti A., Greco S., Pellegrino P. et al. Macrophages and immune responses in uterine fibroids. Cells 2021;10(5):982. DOI: 10.3390/cells10050982

8. Szydłowska I., Grabowska M., Nawrocka-Rutkowska J. et al. Markers of inflammation and vascular parameters in selective progesterone receptor modulator (ulipristal acetate)-treated uterine fibroids. J Clin Med 2021;10(16):3721. DOI: 10.3390/jcm10163721

9. Malyshkina A.I., Sotnikova N.J., Posiseeva L.V., Antzyferova J.S. Immune parameters of the peritoneal fluid in uterine myoma. Prognostic relevance. Medicinskaja immunologija = Medical Immunology (Russia) 2005;7(4):437–40. (In Russ.). DOI: 10.15789/1563-0625-2005-4-437-440

10. Konenkov V.I., Koroleva E.G., Orlov N.B. et al. Blood serum levels of proinflammatory cytokines (IL-1β, IL-6, TNFα, IL-8, IL-12p70, and IFNγ) in patients with uterine myoma. Bull Exp Biol Med 2018;165(5):698–701. DOI: 10.1007/s10517-018-4245-0

11. Sikorski R., Kapeć E., Zaleska W. Serum levels of proinflammatory cytokines in women with uterine myomas. Ginekol Pol 2001;72(12A):1485–8. PMID: 11883301

12. Novikov V.V., Karaulov A.V. Storm of soluble differentiation molecules in COVID-19. Immunologiya 2022;43(4):458–67. DOI: 10.33029/0206-4952-2022-43-4-458-467

13. Bleijs D.A., Geijtenbeek T.B., Figdor C.G., van Kooyk Y. DC-SIGN and LFA-1: a battle for ligand. Trends Immunol 2001;22(8):457–63. DOI: 10.1016/S1471-4906(01)01974-3

14. Wu M., Tong X., Wang D. et al. Soluble intercellular cell adhesion molecule-1 in lung cancer: A meta-analysis. Pathol Res Pract 2020;216(10):153029. DOI: 10.1016/j.prp.2020.153029

15. Kovács P., Joó J.G., Tamás V. et al. The role of apoptosis in the complex pathogenesis of the most common obstetrics and gynaecology diseases. Physiol International 2020;107(1):106–19. DOI: 10.1556/2060.2020.00014

16. Guégan J.P., Ginestier C., Charafe-Jauffret E. et al. CD95/Fas and metastatic disease: What does not kill you makes you stronger. Semin Cancer Biol 2020;60:121–31. DOI: 10.1016/j.semcancer.2019.06.004

17. Basta P., Mach P., Pitynski K. et al. Differences in the blood serum levels of soluble HLA-G concentrations between the menstrual cycle phases and menopause in patients with ovarian endometriosis and uterine leiomyoma. Neuro Endocrinol Lett 2009;30:91–8. PMID: 19300397

18. Mamaeva М.Е., Novikov D.V., Alyasova А.V. et al. The content of oligomeric and total fractions of soluble CD38 molecules in blood serum of patients with hysteromyoma. Sovremennye tehnologii v medicine = Modern Technologies in Medicine 2014;6(4):140. (In Russ.).

19. Mamaeva М.Е., Shumilova S.V., Kazatskaya Zh.А. et al. The content of soluble HLA Class I and HLA-DR molecules in serum in patients with uterine cervix and body pathology. Sovremennye tehnologii v medicine = Modern Technologies in Medicine 2014;6(2):85. (In Russ.).